scholarly journals Course of intrahospital coronavirus infection (COVID-19) against the background of preventive and curative administration of peptide immunotropic drugs as part of complex therapy

2020 ◽  
Vol 2 (3) ◽  
pp. 8-13
Author(s):  
Sergey V. Petlenko ◽  
Vyacheslav S. Smirnov ◽  
Victor V. Rudenko
Keyword(s):  
Viral Infections ◽  
Clinical Laboratory ◽  
Patient Treatment ◽  
Immunomodulatory Activity ◽  
Manufacturing Companies ◽  
Russian Scientific Research Institute ◽  
Complex Therapy ◽  
Prevention And Treatment ◽  
Coronavirus Infection ◽  
Respiratory Viral Infections

Due to the lack of COVID-19 specific preventive measures with a prophylactic and therapeutic (as part of complex therapy) purpose, various drugs were used as humanitarian aid from manufacturing companies to prevent influenza and SARS in St. Petersburg hospitals. The study of Russian Scientific Research Institute of Traumatology and Orthopedics named after R.R. Vreden patient treatment shows the possibility of using drugs containing a synthetic regulatory thymus peptide (L-glutamine-L-tryptophan-thymogen) as an active ingredient in a patient with an in-hospital coronavirus infection. This compound has a number of extra- and intracellular immunotropic effects of key importance in the pathogenesis of respiratory viral infections, including coronavirus etiology. The components have an indirect antiviral effect against acute respiratory viral infections, comprising COVID-19. This led to the use of drugs containing thymogen for the prevention and treatment of COVID-19. The use of immunotropic agents promoted the rapid involution in the patient of clinical, laboratory and instrumental (radiological) signs of the disease and its uncomplicated course both in the primary infection and the development of superinfection cases. The study has shown that the use for the prevention and treatment (as part of complex therapy) of drugs with immunomodulatory activity, as well as those capable of affecting various links in the pathogenesis of pulmonary lesions in coronavirus infection, seems to be highly relevant and justified.

scholarly journals Aminodihydrophthalazinedione sodium in prevention, therapy and rehabilitation of patients with respiratory diseases

2021 ◽  
Vol 23 (3) ◽  
pp. 296-303
Author(s):  
Dmitry I. Trukhan ◽  
◽  
Natalya V. Bagisheva ◽  
Anna V. Mordyk ◽  
Ekaterina Yu. Nebesnaya ◽  
...  
Keyword(s):  
Viral Infections ◽  
Laboratory Diagnostics ◽  
The Novel ◽  
Modern Approach ◽  
Prevention Therapy ◽  
Prevention And Treatment ◽  
Respiratory Pathology ◽  
Coronavirus Infection ◽  
Respiratory Viral Infections ◽  
Novel Coronavirus

The modern approach to the prevention and treatment of acute respiratory viral infections consists in the use of drugs that increase the body’s defenses, helping to create a barrier to the penetration of the virus. Immunomodulators exhibit a nonspecific effect in acute respiratory viral infections, which makes it possible to use them against various types of respiratory viruses without accurate laboratory diagnostics and expands clinical capabilities. In the first part of the review, the features of sodium aminodihydrophthalazinedione and the experience of its use in respiratory pathology are considered. The pandemic of the novel coronavirus infection (COVID-19), spread by the novel coronavirus SARS-CoV-2, has become a challenge to health systems around the world. The second part of the review reviews the results of the first studies on the use of sodium aminodihydrophthalazinedione for the prevention and treatment of new coronavirus infection. Recently, much attention has been paid to the long-term consequences of the postponed coronavirus infection. In the final part of the review, various aspects of the “post-COVID syndrome” are discussed and the possibilities of aminodihydrophthalazinedione sodium at the stage of rehabilitation after a coronavirus infection are discussed.

The association of respiratory viruses with oxidative stress and antioxidants. Implications for the COVID-19 pandemic

2021 ◽  
Vol 27 ◽  
Author(s):  
Marina Darenskaya ◽  
Liubov Kolesnikova ◽  
Sergei Kolesnikov
Keyword(s):  
Oxidative Stress ◽  
Antioxidant Defense ◽  
Viral Infections ◽  
Respiratory Viruses ◽  
Oxygen Species ◽  
Prevention And Treatment ◽  
Coronavirus Infection ◽  
Influenza Pneumonia ◽  
Respiratory Viral Infections ◽  
Fat Soluble Vitamins

: The spread of a new strain of coronavirus, SARS-CoV-2, a pandemic poses serious health problem for all humanity. In comparison with the previous outbreaks of coronavirus infection in 2002 and 2012, COVID-19 infection has high rates of lethality, contagiousness and comorbidity. The effective methods of prevention and treatment are extremely limited. Oxidative stress is actively involved in the mechanisms of initiation and maintenance of violations of homeostatic reactions in respiratory viral infections. It is important to stop systemic inflammation aimed at "extinguishing" the cytokine "storm", caused by the production of reactive oxygen species. Antioxidant defense medications such as vitamin C, N-acetylcysteine, melatonin, quercetin, glutathione, astaxanthin, polyphenols, fat-soluble vitamins, and polyunsaturated fatty acids have proven well in experimental and clinical studies of influenza, pneumonia, and other respiratory disorders. The use of medications with antioxidant activity could be justified and most probably would increase the effectiveness of the fight against new coronavirus.

Organisation of Medical Care for Pregnant Women, Women in Labor and New Mothers with COVID-19 Infection

2020 ◽  
pp. 47-56
Author(s):  
Vladimir Klimov
Keyword(s):  
Pregnant Women ◽  
Physiological Condition ◽  
Viral Infections ◽  
Physiological Changes ◽  
Insufficient Information ◽  
Present Stage ◽  
New Mothers ◽  
High Affinity ◽  
Coronavirus Infection ◽  
Respiratory Viral Infections

Although pregnancy is a physiological condition, this category of women has a high probability of severe acute respiratory viral infections, and a fairly high affinity to these diseases, due to physiological changes in the immune system. In 2009/2010, during the A(H1N1)09 virus that caused pig flu, the morbidity among pregnant women reached 27.9%. In addition, such viruses as SARS-CoV and MERS-CoV are known to contribute to severe complications in pregnancy and lead to the need for endotracheal intubation and hospitalisation of women to the intensive care unit, and in some cases, diseases caused by these viruses can cause kidney failure and even death, which reaches 25% when SARS-CoV is detected among pregnant women. At the present stage, there is insufficient information on the new coronavirus infection impact on pregnant women and newborns, and there are no reliable recommendations as to the management of pregnant women when COVID-19 is diagnosed. In this article, we will try to summarise information on managing such patients based on the cases when coronavirus was diagnosed in pregnant women.

scholarly journals Efficacy and safety of Anaferon for children and Anaferon for the prevention and treatment of influenza and other acute respiratory viral infections: systematic review and meta-analysis

2021 ◽  
Vol 5 (5) ◽  
pp. 335-347
Author(s):  
N.A. Geppe ◽  
◽  
A.L. Zaplatnikov ◽  
E.G. Kondyurina ◽  
O.I. Afanasieva ◽  
...  
Keyword(s):  
Systematic Review ◽  
Therapeutic Efficacy ◽  
Disease Duration ◽  
Viral Infections ◽  
Respiratory Infections ◽  
Meta Analysis ◽  
Acute Respiratory Infections ◽  
Efficacy And Safety ◽  
Prevention And Treatment ◽  
Respiratory Viral Infections

Aim: to evaluate the efficacy and safety of Anaferon and Anaferon for children for the prevention and treatment of of acute respiratory viral infections (ARVI)/influenza using meta-analysis. Patients and Methods: the meta-analysis included data from 11 randomized clinical trials (RCTs) involving 3079 patients aged 1 month to 69 years, of which: 1729 people were included in the meta-analysis of the preventive drugs efficacy, 1550 patients — in the meta-analysis of the therapeutic efficacy of Anaferon for children. The evaluation of the therapeutic efficacy was conducted according to the criteria "disease duration" and/or "fever duration", the evaluation of the preventive efficacy was conducted according to the criterion "the proportion of patients not falling ill with ARVI/influenza". The safety was evaluated taking into account the number of adverse events (AEs). Statistical methods included the exact Fisher criterion, the Student criterion, fixed and random effects models, the Z-test, the Cochrane-Mantel-Hensel criterion, Cochrane Q-statistics and the I2 coefficient, the Breslow-Day test, the calculation of relative risk (RR), odds ratios (OR) and their 95% confidence intervals (CI). Results: according to the criterion "the proportion of patients not falling ill with ARVI/influenza", the RR of Anaferon for children was 1.2 [95% CI 1.2; 1.3] with an OR of 2.2 [95% CI 1.7; 2.9], while for Anaferon, the RR was 6.7 [95% CI 3.8; 11.8] with an OR of 20.1 [95% CI 9.2; 44.0]. At the same time, the proportion of patients without ARVI/influenza during Anaferon intake exceeded that in the absence of preventive intervention by almost 8 times, and during Anaferon for children intake — 1.3 times vs. placebo. When evaluating the therapeutic effect of Anaferon for children, it was found that the average disease duration was 1.4 times shorter than during placebo intake, and was 4.71±2.53 days (p<0,001). The average fever duration was 2.19±1.21 days vs. 3.22±1.81 days during placebo intake (p<0,001). According to the criterion "disease duration", the weighted average effect value was 1.05 [95% CI 0.44; 1.67], according to the criterion "fever duration" — 0.97 [95% CI 0.61; 1.33] (p<0.001, p-value of the two-tailed Z-test; random effects model). The therapeutic efficacy of Anaferon for children did not depend on the etiology of ARVI, the symptoms, and the presence of comorbidity (asthma). The total number of AEs is similar to those in the comparison group. Conclusion: the conducted review and meta-analysis concerning the efficacy and safety of Anaferon and Anaferon for children for the treatment and prevention of ARVI/influenza allow us to conclude the following: 1) Anaferon for children is effective and safe for the treatment of influenza and other acute respiratory infections, regardless of the pathogen and the presence of comorbidity (asthma); 2) Anaferon and Anaferon for children are effective and safe for the prevention of acute respiratory infections/influenza, including patients with concomitant bronchopulmonary pathology and frequently ill children. KEYWORDS: ARVI, influenza, prevention, treatment, meta-analysis, Anaferon, Anaferon for children. FOR CITATION: Geppe N.A., Zaplatnikov A.L., Kondyurina E.G. et al. Efficacy and safety of Anaferon for children and Anaferon for the prevention and treatment of influenza and other acute respiratory viral infections: systematic review and meta-analysis. Russian Medical Inquiry. 2021;5(5):335–347 (in Russ.). DOI: 10.32364/2587-6821-2021-5-5-335-347.

scholarly journals Current, effectiveness of therapy and outcomes of new coronavirus infection: preliminary analysis

2020 ◽  
Vol 12 (2) ◽  
pp. 27-38
Author(s):  
Sergey A. Sayganov ◽  
Vadim I. Mazurov ◽  
Igor G. Bakulin ◽  
Elguja L. Lataria ◽  
S A Artyushkin ◽  
...  
Keyword(s):  
Preliminary Analysis ◽  
Clinical Laboratory ◽  
Treatment Options ◽  
Fatal Outcome ◽  
Age Groups ◽  
Statistical Processing ◽  
Complex Therapy ◽  
Symptom Complex ◽  
Coronavirus Infection ◽  
D Dimer

Relevance. Verification of a new coronavirus infection (COVID-19) requires clear algorithms for the diagnosis and treatment of patients, depending on clinical, laboratory and instrumental dates. Timely and informed decisions on optimizing management tactics and prescribing proactive anti-inflammatory therapy before development of a complete symptom complex life threatening conditions are needed in some cases. Aim of the study. To analyze the course and outcomes of a new coronavirus infection, depending on the initial characteristics of the patients and treatment options. Materials and methods. A preliminary analysis of the case histories of 129 people hospitalized in the center for treating patients with a new coronavirus infection at North-Western State Medical University n.a. I.I. Mechnikov was made by random sampling. Among the hospitalized patients there were 67 men (51.9%), the average age was 57.9 16.4 years, 62 women (48.1%), and the average age was 60.2 13.6 years. During hospitalization, all patients underwent standard clinical laboratory and instrumental examination, as well as determination of saturation (SpO2), markers of the cytokine storm (CRP, ferritin, AST, D-dimer, fibrinogen, lymphocytes), compute tomography (CT) of the lungs. The effectiveness and safety of therapy was evaluated by the outcome (recovery, death), as well as by the presence of adverse events in the background of the therapy. Statistical processing of the research results was carried out using the Statistica 12 for Windows application software package, the significance of differences between the two relative values was evaluated using the Student t-test (t 2, p 0.05). Results. Fatal outcomes were significantly more frequently recorded among patients of older age groups and males. The presence of concomitant diseases such as obesity, diabetes mellitus, pathology of the cardiovascular system was accompanied by more frequent fatal outcomes. That allows considering comorbidity as a risk factor for severe course and poor prognosis of COVID-19. However, in general, in the presence of the indicated forms of concomitant diseases, it was not possible to establish significant differences with the outcomes of COVID-19, which may be due to an insufficient amount of patients. Predictors of fatal outcome was low values of saturation, the presence of respiratory failure, a significant amount of lung tissue damage (CT-3-4), as well as high values of CRP, ferritin, AST, D-dimer, neutrophilia, lymphopenia, thrombocytopenia. The use of anticytokine drugs (ACD) in complex therapy can be considered a favorable predictor of outcome, which indicates the advisability of wider use. The materials of the study allow not only a preliminary assessment of the course and effectiveness of complex therapy using anticytokine drugs with COVID-19 in patients with comorbid diseases, but also to develop therapeutic and diagnostic algorithms in patients of this category.

scholarly journals Associative influence of new coronavirus infection SARS-CoV-2 during pregnancy on formation of neurological disorders in newborns: clinical case

2021 ◽  
Vol 38 (5) ◽  
pp. 165-172
Author(s):  
T. P. Shevlyukova ◽  
Zh. K. Zhusupova ◽  
E. N. Solovyeva
Keyword(s):  
Pregnant Women ◽  
Neurological Disorders ◽  
Clinical Case ◽  
Viral Infections ◽  
Acute Inflammatory Response ◽  
Infected Mother ◽  
Neuroimmune Interactions ◽  
The World ◽  
Coronavirus Infection ◽  
Respiratory Viral Infections

The Severe Acute Respiratory Syndrome caused by Coronavirus-2 (SARS-CoV-2) has a destructive impact on the population all over the world. In this scenario, the extent, to which the disease will affect more vulnerable individuals, such as pregnant women, is a major concern. Since pregnancy can be a risk factor for respiratory viral infections, there are significant differences regarding the severity of COVID-19 between pregnant and non-pregnant women. In these circumstances, there arises a serious problem associated with the possibility of harm to the health and neuropsychiatric development of the posterity of infected mothers. The acute inflammatory response observed during the disease can lead to several types of nervous system disorders in the newborn. In the light of neuroimmune interactions on the mother-fetus hematoplacental relationship, a clinical case is described that reflects the consequences for the nervous and psychoneurological development of the newborn from SARS-CoV-2 infected mother.

scholarly journals The use of innovative domestic interferon inducer for the prevention and treatment of acute respiratory viral infections in children

2016 ◽  
Vol 1 (1) ◽  
pp. 50-53 ◽  
Author(s):  
Y. L. Mizernitskiy
Keyword(s):  
Clinical Efficacy ◽  
Viral Infections ◽  
Mechanisms Of Action ◽  
Efficacy And Safety ◽  
Interferon Inducer ◽  
Interferon Inducers ◽  
Treatment And Prevention ◽  
Prevention And Treatment ◽  
Respiratory Viral Infections

The article presents data on the place of the modern endogenous interferon inducers in the treatment and prevention of influenza and ARVI in children and the mechanisms of action. The focus is on the domestic antiviral innovation Kagocel which demonstrated high clinical efficacy and safety in a number of multi-center, blind, placebo-controlled studies of the treatment and prevention of ARVI/flu in children over 2 years old.

Respiratory viral infections including caused by coronaviruses in oncological and oncohematological patients

2021 ◽  
Vol 21 (3) ◽  
pp. 119-122
Author(s):  
Alena V. Kuleshova ◽  
Inna P. Iskova ◽  
Ekaterina E. Kiseleva ◽  
Vitaliy N. Chebotkevich
Keyword(s):  
Cancer Patients ◽  
Viral Infections ◽  
Respiratory Viruses ◽  
Infectious Complications ◽  
Leningrad Region ◽  
Hematological Cancer ◽  
Russian Research Institute ◽  
Coronavirus Infection ◽  
Respiratory Viral Infections ◽  
Russian Research

BACKGROUND: Patients with cancer are prone to developing infectious complications. They significantly aggravate the course of the underlying disease and worsen the quality of life of patients. The emergence of infections is largely promoted by immunosuppression associated with the use of cytostatic drugs, high-dose chemotherapy and hematopoietic stem cell transplantation in hematological cancer patients. Among infectious agents, respiratory viruses, especially influenza viruses, play an important role. The urgency of this problem has increased many times in connection with the development of the COVID-19 pandemic. AIM: To study the features of the course of respiratory infections, including coronavirus (seasonal and COVID-19), infections in cancer and oncohematological patients during hospitalization and in outpatient settings. MATERIALS AND METHODS: The study of the frequency and course of infectious complications in cohorts of patients with oncological diseases, who were under dispensary supervision in the polyclinic in Kirovsk, Leningrad region. Retrospective analysis of the frequency and characteristics of the course of coronavirus infection caused by HCoVs (OC43, 229E, NL63, HKU1) in patients treated at the clinics of the Russian research institute of Hematology and Transfusionology. Prospective study of the coronavirus COVID-19 of patients hospitalized at the Russian research institute of Hematology and Transfusionology and at the Kirov interdistrict hospital in Leningrad Region during the period of its conversion to specialized infection diseases hospital. RESULTS: Coronavirus infection caused by HCoVs (OC43, 229E, NL63, HKU1), occurs in hematological cancer patients more often in association with other respiratory viruses. In the cases of detection of the SARS-CoV-2 in hospitalized patients, they need to be transferred to specialized infectious hospitals. CONCLUSIONS: Respiratory viral infections are risk factors in cancer and oncohematological patients. Outpatient oncological and oncohematological patients require constant dispensary observation and special attention during the COVID-19 pandemic, outbreaks of influenza and other viral infections.

PROSPECTS FOR THE CREATION OF MEDICINES BASED ON A NATURAL ADAPTOGEN IN THE COMPLEX THERAPY OF VIRAL INFECTIONS

2022 ◽  
pp. 21-28
Author(s):  
А.М. ОМАРИ ◽  
Т.А. АРЫСТАНОВА
Keyword(s):  
Glycyrrhizic Acid ◽  
Viral Infections ◽  
Licorice Root ◽  
Root Extract ◽  
Current State ◽  
Complex Therapy ◽  
Prevention And Treatment ◽  
The Creation ◽  
Licorice Root Extract

В статье описано современное состояние распространения, переработки и использования солодки в Казахстане. Представлены литературные данные использования компонентов корня солодки в создании лекарственных средств для профилактики и лечения иммунодефицитного состояния при вирусных инфекциях. Обобщены литературные данные о комбинированных препаратах, содержащих экстракт корня солодки, глицирризиновую кислоту. The article describes the current state of distribution, processing and use of licorice in Kazakhstan. The literature data on the use of licorice root components in the creation of medicines for the prevention and treatment of immunodeficiency in viral infections are presented. The literature data on combined preparations containing licorice root extract and glycyrrhizic acid are summarized.

Sign in / Sign up

Export Citation Format

Share Document